Ampliphi Biosciences Corp (APHB) 1.50 $APHB AmpliPhi

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ampliphi Biosciences Corp (APHB) 1.50 $APHB

AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics
BusinessWire - Thu Jun 02, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the European Patent Office has issued a decision to grant AmpliPhi patent No. 2136826, for the "Beneficial effects of bacteriophage treatments". A corresponding patent has been granted in Australia and a species-specific patent for Pseudomonas aeruginosa has been granted in the United States. Additional patents are pending in Canada, Japan and the United States.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
BusinessWire - Tue May 31, 9:53PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the pricing of a registered direct offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one-half of a share of common stock of AmpliPhi at a combined purchase price of $2.35. The warrants will be immediately exercisable at a price of $2.25 per full share of common stock for a period of five years from closing, which is expected to occur on June 3, 2016.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences' CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International
BusinessWire - Tue May 31, 9:38AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's Chief Executive Officer, will participate in a panel discussion at this year's BIO International Convention.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND
BusinessWire - Tue May 24, 7:36AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its Phase 1 clinical trial to evaluate the safety of AB-SA01, AmpliPhi's proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections, administered topically to the intact skin of healthy adults. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army and at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016
BusinessWire - Tue May 10, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the quarter ended March 31, 2016 on Thursday, May 12. AmpliPhi management will host a conference call at 8:30 a.m. Eastern Time on May 13, 2016 to review financial results and provide a corporate update.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
BusinessWire - Wed Apr 20, 11:30AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi's proprietary phage cocktail AB-SA01.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon
BusinessWire - Thu Apr 14, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
BusinessWire - Tue Apr 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Reports Full-Year 2015 Financial Results
BusinessWire - Wed Mar 30, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended December 31, 2015.
XON: 24.38 (+0.37), APHB: 1.50 (-0.03)

AmpliPhi Biosciences to Host Full-Year 2015 Financial Results Conference Call and Webcast on March 30, 2016
BusinessWire - Tue Mar 29, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the fiscal year ended December 31, 2015 on Wednesday, March 30, 2016. AmpliPhi management will host a conference call at 4:30 pm Eastern Time on March 30, 2016 to review financial results and provide a corporate update.
XON: 24.38 (+0.37), APHB: 1.50 (-0.03)

AmpliPhi Biosciences CEO to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's CEO, will present a corporate overview on Tuesday, March 15, 2016 at the 28th Annual ROTH Conference at the Ritz Carlton in Dana Point, California.
XON: 24.38 (+0.37), APHB: 1.50 (-0.03)

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 247.85 (-1.13), AZN: 31.15 (+0.02), CEMP: 18.00 (-0.08), APHB: 1.50 (-0.03), GLPG: 53.01 (+0.11)

AmpliPhi Biosciences Announces Award of Federal Research Grant from Australia to its Collaboration Partner, Westmead Institute
BusinessWire - Tue Feb 09, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, congratulates the Westmead Institute's Centre for Infectious Diseases and Microbiology for winning an AUD $860,000 grant from the Australian Government to isolate and develop phages that target two serious human pathogens, E. Coli and Klebsiella. AmpliPhi will participate in the project by providing its proprietary expertise in bacteriophage isolation, characterization and manufacturing scale-up.
XON: 24.38 (+0.37), APHB: 1.50 (-0.03)

Acinetobacter Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/923dq5/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acinetobacter Infections Overview - Therapeutics Development - Pipeline Products for Acinetobacter Infections - Overview - Pipeline Products for Acinetobacter Infections - Comparative Analysis - Acinetobacter Infections - Therapeutics under Development by Companies - Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes - Acinetobacter Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acinetobacter Infections - Products under Development by Companies - Acinetobacter Infections - Products under Investigation by Universities/Institutes - Acinetobacter Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca Plc - AvidBiotics Corp. - Emergent BioSolutions Inc. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FAB Pharma - FOB Synthesis, Inc. - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/92...netobacter
TTPH: 4.16 (+0.08), SYN: 1.72 (+0.02), EBS: 33.24 (+0.90), SRPT: 23.67 (-0.22), PFE: 36.78 (+0.04), AZN: 31.15 (+0.02), AKAO: 3.75 (-0.18), APHB: 1.50 (-0.03)

Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 11.07 (+0.01), CYCC: 4.69 (-0.11), HZNP: 18.73 (-0.13), KMDA: 3.96 (+0.11), GSK: 44.04 (+0.16), AKTX: 9.48 (+0.69), APHB: 1.50 (-0.03), CNCE: 11.70 (-0.16), GLPG: 53.01 (+0.11)

Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 11.07 (+0.01), PFE: 36.78 (+0.04), AKAO: 3.75 (-0.18), GLYC: 8.60 (+0.48), GSK: 44.04 (+0.16), APHB: 1.50 (-0.03), SRPT: 23.67 (-0.22), ACH: 8.29 (+0.08), AZN: 31.15 (+0.02)

AmpliPhi Biosciences doses CRS patient with AB-SA01 in Phase 1 clinical trial
M2 - Thu Jan 21, 3:51AM CST
Antibacterial company AmpliPhi Biosciences (NYSEMKT:APHB) revealed on Wednesday that it has started treatment of the first patient under its Phase 1 clinical trial of AB-SA01 in Staphylococcus aureus (S. aureus) infections with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
APHB: 1.50 (-0.03)

AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
BusinessWire - Wed Jan 20, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
XON: 24.38 (+0.37), APHB: 1.50 (-0.03)

AmpliPhi Biosciences Announces Appointment of Steve R. Martin as Chief Financial Officer
BusinessWire - Tue Jan 19, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Steve R. Martin has been appointed as its new Chief Financial Officer. He will be based in AmpliPhi's San Diego office.
A: 46.14 (-0.44), XON: 24.38 (+0.37), APRI: 0.36 (+0.03), APHB: 1.50 (-0.03), HOLX: 36.57 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading